uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer
Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro.
Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Obstetrics and Gynaecology. (Klinisk och experimentell reproduktionsbiologi/Olovsson)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Obstetrics and Gynaecology. (Klinisk och experimentell reproduktionsbiologi/Olovsson)
Show others and affiliations
2013 (English)In: Menopause: The Journal of the North American Menopause, ISSN 1072-3714, E-ISSN 1530-0374, Vol. 20, no 2, 162-168 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE:

The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.

METHODS:

A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.

RESULTS:

In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitor-treated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.

CONCLUSIONS:

Our findings suggest that sexual dysfunction in aromatase inhibitor-treated women is a greatly underestimated problem.

Place, publisher, year, edition, pages
2013. Vol. 20, no 2, 162-168 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-185540DOI: 10.1097/gme.0b013e31826560daISI: 000314342600010PubMedID: 22990756OAI: oai:DiVA.org:uu-185540DiVA: diva2:572043
Available from: 2012-11-26 Created: 2012-11-26 Last updated: 2017-12-07Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Stavreus-Evers, AnneliKallak, Theodora KunovacSundström Poromaa, Inger

Search in DiVA

By author/editor
Stavreus-Evers, AnneliKallak, Theodora KunovacSundström Poromaa, Inger
By organisation
Obstetrics and Gynaecology
In the same journal
Menopause: The Journal of the North American Menopause
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 531 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf